Allergan Archives - DelveInsight

Allergan

Presbyopia Treatment Market | Novartis | Visus | AbbVie
How will Pharmacotherapies help the growing number of Presbyopes?

Presbyopia is the gradual loss of near-focusing ability that occurs with age—a condition that occurs when people get older and prevails as a quite common one in many individuals. The reasons for t...


Gastroparesis market size
New Hopes; New Horizons: Gastroparesis Market Has Mighty Treatment Options On Its Sleeves

The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in...


Wet Age-related macular degeneration treatment market
Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill th...


pharma news
Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion. Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dys...


Pharma news
AbbVie Sells bonds to Fund Allergan takeover

AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan.  AbbVie this year in June has agreed to buy Allergan for USD 63 Billion, which is one of the ...


Migraine Treatment
A New Era for Migraine Treatment and CGRP antibodies

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability.According to the Migraine Trust Organization, Migraine is ranked as the 7t...


Pharma News
Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotec...

Daiichi Sankyo announced the submission of a New Drug Application (NDA) of DS-8201 to Japan's Ministry of Health, Labour and Welfare (MHLW).DS-8201 [fam-] trastuzumab deruxtecan), is an inves...


Diabetic Gastroparesis Market
Diabetic Gastroparesis Market Outlook

Gastroparesis is a condition that affects the movement of the food in the stomach and intestines and causes distress leading to bloating, nausea, and heartburn. If the condition is due to Diabetes...


World Pharma News
Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan

Sanifit raises USD 80.9 M to advance Calciphylaxis PipelineSanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The ...


the business cocktail
AgomAb Therapeutics raises $23.5M; Allergan’s eye drug; Good news for the patients; Dyne Th...

AgomAb Therapeutics raises USD 23.5 million for its agomAbsA Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23....


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.